caprotec bioanalytics has developed a ground-breaking, proprietary technology to reduce the complexity of protein mixtures and samples in a targeted and directed manner.
caprotec's Capture Compound Mass Spectrometry (CCMS) Technology is based on multifunctional small molecules (Capture Compoundsâ„¢) that are used to target, capture, and isolate proteins based on their functionality. For many applications, CCMS is clearly superior to shotgun approaches - thus addressing an unmet need in the proteomics community.
Funding Rounds (3) - $16MUpdate
Current Team (1)Update
|Aug 12, 2016||mass-spec-capital.com - Caprotec Bioanalytics GmbH. (1/10/08). "Press Release: Life Science Start-up Caprotec Bioanalytics Receives Additional Venture Capital Funding". Berlin.|
|May 9, 2011||(see Boston Tech Flash) - Caprotec Bioanalytics raises 2100000 in venture round|
|May 17, 2010||PE HUB - Caprotec Bioanalytics Raises €4 Nillion|
|Feb 6, 2008||OnBioVC - Caprotec Bioanalytics, GmbH: Series B $8.8M|
Berlin, Berlin 12489